| Description |
1 online resource (209 pages) |
| Series |
Colloquium Series on Integrated Systems Physiology: From Molecule to Function |
|
Colloquium Series on Integrated Systems Physiology: From Molecule to Function
|
| Contents |
Preface; Inflammation and the Endocannabinoid System; 1.1 Introduction; 1.2 Cannabinoid 1 Receptor; 1.3 Cannabinoid 2 Receptor; 1.4 Other Receptors and Ligands; 1.5 Modulation of the Inflammatory Immune Response by the Endocannabinoid System ; 1.6 Conclusions; Cannabinoids in Multiple Sclerosis; 2.1 Multiple Sclerosis; 2.1.1 Etiology ; 2.1.2 Pathology and Symptoms of Multiple Sclerosis; 2.1.3 Current Treatments for Multiple Sclerosis; 2.2 Cannabinoids in Multiple Sclerosis; 2.2.1 Experimental Autoimmune Encephalomyelitis Animal Models; 2.2.2 Clinical Data; 2.2.3 Tolerability of Cannabinoids |
|
2.3 Concluding Remarks and Future DirectionsHuntington's Disease and the Endocannabinoid System; 3.1 Huntington's Disease; 3.2 Neuroinflammation in Huntington's Disease; 3.3 The Management of Neuroinflammation in Huntington's Disease; 3.4 Endocannabinoid System in Huntington's Disease; 3.5 Modulation of the Endocannabinoidal System to Minimize Neuroinflammation and Neurodegeneation in Huntington's Disease; Alzheimer's, Neuroinflammation and the Endocannabinoid System; 4.1 Introduction to Alzheimer's Disease; 4.2 Alzheimer's Disease Treatments and the Endocannabinoid System |
|
4.3 Cannabinoid Receptors4.4 Neuroinflammation in Alzheimer's Disease; 4.5 Microglia in Alzheimer's Disease; 4.6 Hippocampal Long-term Potentiation in Models of Alzheimer's Disease; 4.7 Cannabinoid Receptors as a Therapeutic Target in Alzheimer's Disease; 4.7.1 Anandamide; 4.7.2 Tetrahydrocannabinol and Cannabidiol; 4.8 Cannabinoids and the Blood Brain Barrier in AD: Hemi-channels and Astrocytes; 4.9 Therapeutic Implications for Cannabinoids; The Endocannabinoid System's Role in Ocular Inflammation; 5.1 The Endocannabinoid System and Marijuana; 5.2 Endocannabinoid System in Ocular Tissue |
|
5.3 The Ocular Inflammatory Response and the Endocannabinoid System 5.4 Diseases Associated with Ocular Inflammation; 5.4.1 Uveitis; 5.4.2 Proliferative Vitreoretinopathy; 5.4.3 Diabetic Retinopathy; 5.5 Conclusion ; Cannabidiol as a Potential Clinical Therapeutic Agent for the Reduction of Pancreatic Inflammation in Early Type 1 Diabetes Mellitus; 6.1 Introduction; 6.2 Pathogenesis of Type 1 Diabetes; 6.3 Current Therapies; 6.4 Cannabidiol Pharmacology; 6.5 Cannabidiol for Prophylaxis of Type 1 Diabetes; 6.6 Conclusion; Role of the Endocannabinoid System in Interstitial Cystitis |
|
7.1 Introduction7.2 Interstitial Cystitis; 7.3 Physiology and Pathophysiology of Interstitial Cystitis ; 7.4 The Endocannabinoid System; 7.5 The Endocannabinoid System in Experimental Interstitial Cystitis; 7.6 Cannabinoid 1 Receptor and Bladder Pathophysiology; 7.7 Cannabinoid 2 Receptor and Bladder Pathophysiology; 7.8 The Endocannabinoid System and Cannabinoids in Cystitis Patients; 7.9 Conclusion; Arthritis and the Endocannabinoid System; 8.1 Introduction to Arthritis ; 8.2 Common Types of Arthritis; 8.2.1 Osteoarthritis; 8.2.2 Rheumatoid Arthritis; 8.2.3 Gout |
| Notes |
8.3 Overview of Cannabinoids |
|
Print version record |
| Form |
Electronic book
|
| Author |
Lehmann, Christian
|
|
Zhou, Juan
|
| ISBN |
9781615047499 |
|
1615047492 |
|
